Floatz logo

Cladribine

Precursor T-Cell Lymphoblastic Leukemia-Lymphoma

Peking University Third HospitalSmall moleculeDormant
D
30/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
15/ 100
Competitive Position
89/ 100

Competitive context

7 Active assets in the Precursor T-Cell Lymphoblastic Leukemia-Lymphoma cohort.

Asset / SponsorPhaseRating
DEXAMETHASONE
Sanofi
Phase 2B
Venetoclax
First Affiliated Hospital of Zhejiang University
Phase 2CCC
Cytosin-Arabinosid
First Affiliated Hospital of Zhejiang University
Phase 2CCC
RANITIDINE
Sanofi
Phase 2CCC
Omacetaxine
First Affiliated Hospital of Zhejiang University
Phase 2CCC

View all 19 →

Same molecule, other indications

Cladribine is also rated in:

relapsing-remitting multiple sclerosisDormant
BBB
Indicative ·
76 / 100
View asset →
lymphoblastic lymphomaDormant
BBB
Indicative ·
75 / 100
View asset →
multiple sclerosisDormant
BBB
Indicative ·
72 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →